None of the 29 investors followed here reported a position in LBRX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a LBRX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 11, 2025 | Nussbaum RanDirector | Purchase at price 15.00 per share. | 1.00M | $15.00M |
| Sep 11, 2025 | Nussbaum RanDirector | — | 411.7K | — |
| Sep 11, 2025 | Pontifax Management 4 G.P. 2015, Ltd.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 15.00 per share. | 1.00M | $15.00M |
| Sep 11, 2025 | Pontifax Management 4 G.P. 2015, Ltd.Beneficial Owner of more than 10% of a Class of Security | — | 411.7K | — |
| Sep 11, 2025 | Vida Ventures Gp Iii, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 15.00 per share. | 333.3K | $5.00M |
| Sep 11, 2025 | Vida Ventures Gp Iii, L.L.C.Beneficial Owner of more than 10% of a Class of Security | — | 548.9K | — |
| Sep 11, 2025 | Deep Track Biotechnology Master Fund LtdBeneficial Owner of more than 10% of a Class of Security | Purchase at price 15.00 per share. | 2.67M | $40.00M |
| Sep 11, 2025 | Deep Track Biotechnology Master Fund LtdBeneficial Owner of more than 10% of a Class of Security | — | 686.1K | — |
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Buy / hold / sell counts